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1. Introduction
The treatment paradigm for multiple myeloma has evolved considerably over the past three
decades with the incorporation of autologous stem cell transplantation (ASCT) in upfront
therapy for eligible patients, and the use of novel agents. As a result, although multiple
myeloma remains an incurable disease, clinical outcomes have significantly improved. In
this chapter we will review the seminal studies that established the role of ASCT in multiple
myeloma and as well as the current controversies with regard to the role of ASCT in the
management of myeloma in the era of novel agents. We will review conditioning regimens,
post-transplant maintenance strategies with novel agents and immune modulation. We will
summarize the current data on early versus late ASCT, single versus tandem transplant and
the role of ASCT in patients with relapsed or progressive disease.
2. The role of autologous stem cell transplantation in multiple myeloma
The advent of autologous stem cell transplantation has changed the therapeutic landscape
for the management of multiple myeloma and has been the standard frontline therapy for
younger patients with normal renal function since the 1990’s. The standard of care for multi‐
ple myeloma patients prior to the incorporation of ASCT was conventional chemotherapy
using melphalan and prednisone with the primary goals of treatment being achievement of
partial response or disease stabilization. Treatment complications and later resistance were
associated with poor outcomes with median overall survival ranged between two and three
years.
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High-dose chemotherapy was initially explored as a therapeutic approach in the 1980’s after
a landmark study demonstrated its effectiveness in inducing 100-percent complete remis‐
sion rates in nine high-risk multiple myeloma and plasma cell leukemia patients after pre‐
conditioning with high-dose melphalan. The observation that high-dose melphalan had
significant anti-tumor activity and could overcome primary drug resistance was confirmed
in a later study.
Since its initial description, there have been seven randomized clinical trials comparing
high-dose ASCT to conventional chemotherapy (Table 1). The first of these trials was con‐
ducted by the Intergroupe Français du Myélome (IFM) in which 200 untreated multiple
myeloma patients under 65 years of age were randomized to receive either conventional
chemotherapy or high dose chemotherapy in combination with ASCT. Response rates were
significantly higher in patients receiving high-dose chemotherapy and ASCT compared to
those who received conventional chemotherapy alone (81% vs 57%, p<0.001). Furthermore,
patients who received high-dose therapy had a higher probability of 5-year event-free sur‐
vival (28% vs 10%, p = 0.01) and estimated 5-year rate of overall survival (52% vs 12%, p
=0.03). Seven years later, the findings from the IFM study were corroborated by the British
Medical Research Council Myeloma VII Trial (MRCM-VII) in a larger 407 patient multicen‐
ter study.
These findings prompted modifications to the disease response criteria as proposed by the
International Myeloma Working Group as the achievement of complete responses (CRs),
which were rare using conventional chemotherapy, became more achievable and, most im‐
portantly, were found to correlate with survival endpoints.
An additional five prospective randomized trials comparing ASCT to conventional chemo‐
therapy followed. Most, but not all, demonstrated superiority of ASCT to conventional che‐
motherapy with respect to higher rates of CR and very good partial responses (VGPR)
which ultimately translated into longer progression-free survival (PFS). An overall survival
(OS) benefit was reported in three of the seven studies [5,6,12]. Differences in methodology
and trial design between studies may account for some of the discordance in results. A sys‐
tematic review and meta-analysis of these randomized trials reported improved overall me‐
dian PFS with no significant improvement in OS following ASCT when compared to
conventional chemotherapy .
In summary, high dose chemotherapy and ASCT has markedly improved the depth of re‐
sponse, overall response rates, and length of progression-free survival in multiple myeloma
patients. Most importantly, ASCT has improved overall survival from a median of 36
months to 50-55 months, thereby establishing it as the standard of care for multiple myelo‐
ma patients under the age of 65 with normal renal function. However, there remains consid‐
erable heterogeneity between myeloma patients with regard to underlying disease
characteristics and post-ASCT clinical responses. A number of prognostic markers have
been identified that influence disease response to chemotherapy, ASCT and survival, specif‐
ically age, elevated β-2-microglobulin levels, LDH and serum free light chain ratio. Addi‐
tionally, the recognition of recurrent chromosomal abnormalities, which have been reported
in as many as 90% of patients has allowed myeloma patients to be categorized into low, in‐
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termediate and high risk groups on the basis of these aberrations. Translocation (4;14),
t(14;20), deletion 17p and gain of 1q have been well associated with poor disease responses
and negatively impact overall survival. A recent update from the IFM group have demon‐
strated a 75% 8-year survival rate in patients who did not have these chromosomal abnor‐
malities and β-2-microglobulin values less than 5.5mg/L.
Trial/group
(Year of
publication)
No.
Patients
Age,
years
Median
Follow-up
Response Rates (%)
(CCT vs ASCT)
EFS, mos
(CCT vs ASCT)
OS, mos
(CCT vs ASCT)
IFM, (1996) 200 <65 7 years
ORR: 57 vs 81
18 vs 28 44 vs 57CR: 5 vs 22
VGPR: 9 vs 16
MAG91 (1998) 185 55-65 58 mos
ORR: 62 vs 86
19 vs 24 50 vs 55
CR: 5 vs 19
BMRC VII, (2003) 407 <65 42 mos
ORR: 67 vs 90
19 vs 31 42 vs 54CR: 8 vs 44
PR: 40 vs 42
Italian MMSG
M97G(2004) 194 50-70 39 mos
ORR: 42 vs 73
15.6 vs 28 42 vs 58+
nCR: 6 vs 25
MAG95 (2005) 190 55-65 120 mos
ORR: 77 vs 70
19 vs 31 42 vs 54
CR +MRD: 20 vs 36
PR: 38.5 vs 26
MR: 18 vs 7
PETHEMA, (2005) 164 <65 44 mos CR: 11 vs 30 33 vs 42 66 vs 61
US Intergroup
9321 (2006) 516 ≤70 76 mos CR: 15 vs 17 14% vs 17%** 38% vs 38%**
Abbreviations: IFM:,Intergroupe Français du Myélome, MAG: Myélome Autogreffe, BMRC: British Medical Research
Council, MMSG: Multiple Myeloma Study Group, PETHEMA: Programa para el Estudio de la Terapéutica en Hemaopa‐
tia Maligna, ORR: Overall response rate, CR: Complete remission, nCR: Near complete remission, VGPR: Very good par‐
tial response, PR: Partial response, MRD: Minimal residual disease, MR: Minimal response
** 7-year estimated EFS and OS rate
Table 1. Randomized trials comparing ASCT to conventional chemotherapy (CCT)
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While clinical outcomes have improved significantly since the widespread implementation
of ASCT, there are several unanswered questions relating to the use of ASCT in multiple
myeloma, particularly in the era of novel therapies, which remain as areas of active investi‐
gation. However, before these controversies can be fully addressed, it is important to under‐
stand the role of novel agents and their impact on myeloma management before discussing
their current use in the context of ASCT.
3. Immune modulation and the advent of novel agents
The concept of immune modulation was formulated and developed after a greater under‐
standing of the complex interaction between myeloma cells and their microenvironment as
well as the discovery that myeloma cells, through a variety of mechanisms, are inherently
able to evade host natural immune defenses, thereby potentiating their own survival. The
immune dysregulation that is known to accompany multiple myeloma is believed to be the
result of multiple biological pathways and mechanisms including excess production of mye‐
loma–derived cytokines, inadequate antigen presentation, resistance to NK-cell lysis and im‐
paired activity of B, T and NK cells. Additionally, multiple myeloma is also associated with
defective humoral and cellular immunity leading to abnormal B-cell differentiation and
function. Reduced numbers of CD4+ T cells, abnormal Th1/Th2 CD4+ T-cell ratios, impaired
cytotoxic T-cell responses, dysfunction of NK and NK T-cells and abnormal dendritic cell
function further compound the immune dysfunction associated with multiple myeloma.
The immunomodulatory drugs (IMiDs), lenalidomide and pomalidomide are thalidomide
analogs that were specifically developed in response to the resurgence of interest in thalido‐
mide after it was incidentally discovered to be an effective treatment in patients with cuta‐
neous leprosy presumably through inhibition of TNFα. Subsequent preclinical trials
revealed that thalidomide, in fact, had several favorable properties that would optimize its
use as an anti-cancer agent.
The IMiDs, were created with the intent to maximize the pleiotropic activity directed against
myeloma cells that was demonstrated by thalidomide, and, in fact are 50,000 times more po‐
tent than thalidomide in their immunomodulatory properties, including CD4+ and CD8+ T-
cell costimulation, Th1 cytokine production, NK and NK T-cell activation, and antibody-
dependent cellular cytotoxicity. Furthermore, they also disrupt the interaction between
myeloma cells and the tumor microenvironment through potent inhibition of angiogenesis
and downregulation of inflammatory cytokines, specifically TNFα, from peripheral blood
mononuclear cells. The IMiDs also directly exert anti-tumor proliferation effects. Additional‐
ly the IMiDs are more capable of stimulating T-cells with without incurring the same degree
of toxicity as thalidomide. The manipulation of the immune system by IMiDs has establish‐
ed their efficacy in the management of multiple myeloma. Lenalidomide and thalidomide,
in addition to the proteasome inhibitor, bortezomib, are considered the main novel agents,
and, in light of their significant disease activity, are now routinely integrated into multiple
myeloma management in ASCT eligible and ineligible patients.
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4. The impact of novel agents on induction and stem cell mobilization
Prior to the widespread use and incorporation of novel agents, the standard induction regi‐
men was vincristine, doxorubicin and dexamethasone (VAD). Dexamethasone was the most
active drug in this regimen and has long since remained the cornerstone of upfront treat‐
ment for multiple myeloma,. The investigation and incorporation of novel agents into induc‐
tion chemotherapy regimens was prompted by the discovery that the quality of disease
response following induction therapy, preceding ASCT, corresponded to better clinical out‐
comes, including subsequent response to ASCT, PFS and OS. Novel agents were initially in‐
vestigated to determine whether the rates of these responses could be improved. Table 3
summarizes the results of published studies using novel agents as part of induction therapy
prior to ASCT.
Thalidomide-based induction regimens were initially compared to VAD and were found to
produce higher VGPR, but not CR, rates prior to transplant.. However, the increased inci‐
dence of thromboembolic complications and drug toxicity rendered the overall benefit of
thalidomide containing regimens somewhat modest. A 10-year clinical follow-up study of
169 myeloma with advanced or refractory disease who were initially treated with thalido‐
mide demonstrated remarkably improved event-free survival and OS in patients with nor‐
mal cytogenetics and non-lambda light chain isotype.
Lenalidomide  and  high-dose  dexamethasone  (RD)  was  compared  to  lenalidomide  and
low-dose  dexamethasone (Rd)  as  initial  therapy in  transplant  eligible  and ineligible  pa‐
tients  and,  while  improved response rates (≥  VGPR) were significantly improved in pa‐
tients  receiving RD,  increased toxicities  and mortality  were also  more pronounced with
this  regimen,  especially  in  patients  older  than  65  years  of  age.  Furthermore,  ASCT  in
combination with RD or Rd improved 3-year OS rates compared to patients who did not
undergo ASCT [92% vs  79%].  Three  drug-combinations  using  lenalidomide,  bortezomib
and dexamethasone  (RVD)  have  also  been  investigated  in  a  few phase  I/II  studies  and
have shown even greater improvements in response rates pre and post-transplant.
The proteasome inhibitor, bortezomib, in combination with dexamethasone was initially
discovered to significantly improve near complete remission (nCR) and CR rates in the land‐
mark IFM2005-1 trial when it was compared to VAD, VAD and dexamethasone, cyclophos‐
phamide, etoposide and cisplatin (DCEP) consolidation, and bortezomib and
dexamethasone followed by DCEP consolidation followed by ASCT. Bortezomib-containing
regimens resulted in higher CR/nCR rates irrespective of disease stage or cytogenetic risk.
Post-transplant, these improved response rates were associated with improved CR, nCR and
VGPR rates as well as improved PFS after a median follow-up of 32 months compared to
patients treated with VAD alone (36 mos vs 30 mos). In the VISTA trial, the addition of bor‐
tezomib to melphalan and prednisone also produced longer OS, and was not found to incur
more resistant relapses in a long term follow-up study. The IFM 2005-1 and VISTA trials
were critical in establishing the role of bortezomib in induction therapy for myeloma. To
further improve the depth of disease response several phase II and III clinical trials have
evaluated the efficacy of adding a third novel agent, either lenalidomide or thalidomide, to
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the bortezomib and dexamethasone backbone, and have demonstrated improved responses
following the addition of a third agent.
Although novel agents have vastly improved the quality of disease response as well as over‐
all response rates in the pre- and post-transplant settings, the use of these agents as part of
induction therapy has resulted in greater difficulties with stem cell collection prior to autolo‐
gous transplant, particularly with the use of lenalidomide and, to a lesser extent, bortezomib
although the exact mechanisms by which stem cell collection is hindered has not yet been
fully elucidated. To address this issue, the International Myeloma Working Group has rec‐
ommended early stem cell mobilization, following 3-4 cycles of induction therapy. Mobiliza‐
tion using G-CSF alone or in combination with cyclophosphamide is typically considered
adequate; and while a large multi-center randomized phase III trial demonstrated a signifi‐
cant improvement in the number of CD34+ cells/kg collected in patients receiving G-CSF
and the CXCR4 inhibitor, plerixafor (AMD3100) compared to G-CSF and placebo, the rou‐
tine use of plerixafor upfront for mobilization remains controversial.
5. The importance of pre-transplant disease response
Complete remissions in the pre-ASCT era were rare, but have now become a very attainable
and desirable treatment goal in the pre and post-transplant settings, especially as they are
considered to be strong surrogate markers for progression-free and survival overall survival
in several studies. The prognostic impact of CR was not fully appreciated until ASCT was
adopted as frontline therapy in the management of multiple myeloma, and this is reflected
in the International Myeloma Working Group response criteria by the introduction of strin‐
gent CRs to further qualify the depth of response [Table 2]. Furthermore, the duration of CR
is also described as a favorable prognostic variable ; however, in several patient subgroups,
including those with a prior history of monoclonal gammopathy of undetermined signifi‐
cance and smoldering myeloma or with low-risk disease achievement of CR appears to be of
less importance.
sCR: Meets criteria for CR plus normal FLC ratio and no clonal cells bone marrow IHC or immunofluorescence
CR: Absence of M protein in serum and urine by immunofixation, < 5% bone marrow plasma cells, no increase of lytic
bone lesions, disappearance of soft tissue plasmacytomas
VGPR: Serum and urine M protein detectable by immunofixation but not on electrophoresis OR ≤ 90% reduction in
serum M-protein plus urine M-protein <100mg/24hr
Abbreviations: IMWG: International Myeloma Working Group, sCR: stringent complete remission, CR: Complete Re‐
mission, VGPR: Very Good Partial Response, FLC: Free Light Chains, IHC: Immunohistochemistry
Table 2. IMWG Complete Response Criteria (Durie et al, Leukemia 2006)
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Author, date of
publication
No. of
patients
Treatment
regimen
Median
follow-up
RR after
induction (%)
RR after
transplant (%)
PFS, median OS
Rajkumar, 2006 207 TD vs Dex 207 CR: 4 vs 0
≥ VGPR: ---
≥ PR: 63 vs 41
CR: ---
≥ VGPR: ---
≥ PR: ---
--- ---
Lokhorst, 2010 536 VAD vs TAD 52 mos CR: 2 vs 3
≥ VGPR: 18 vs 37
≥ PR: 57 vs 71
CR: 12 vs 14
≥ VGPR: 44 vs 54
≥ PR: 76 vs 84
22 vs 34 mos 60 vs 73 mos
Harousseau,
2010
482 VAD vs VD 31.2 mos CR/nCR: 6.4 vs
14.8
≥ VGPR: 15.1 vs
37.7
≥ PR: 62.8 vs 72.5
CR/nCR: 18.4 vs
35
≥ VGPR: 37.2 vs
54.3
≥ PR: 77.1 vs 80.3
29.7 vs 36
mos
3 yr OS
77.4% vs
81.4%
Cavo, 2010 480 VTD vs TD 36 mos CR/nCR: 31 vs 11
≥ VGPR: 62 vs 28
≥ PR: 93 vs 79
CR/nCR: 55 vs 41
≥ VGPR: 82 vs 64
≥ PR: 93 vs 84
68 % vs
56%*
86% vs
84%*
Rajkumar, 2010 445 RD vs Rd 35.8 mos CR: 5 vs 4
≥ VGPR: 71vs 26
≥ PR: 81 vs 70
----
----
----
19 vs 25 mos 2yr OS 87%
vs 75%
Moreau, 2011 199 VD vs vtD 32 mos CR: 22 vs 31
≥ VGPR: 36 vs 49
≥ PR: 81 vs 88
CR: 52 vs 61
≥ VGPR: 58 vs 74
≥ PR: 86 vs 89
30 vs 26 mos ---
Rosinol, 2012 386 VTD vs TD vs
VBMCP/
VBAD/B
35.2 mos CR: 35 vs 14 vs 21
≥ VGPR: 25 vs 15
vs 15
≥ PR: 25 vs 33 vs
39
CR: 46 vs 24 vs 38
≥ VGPR: ---
≥ PR: ---
56.2 vs 28.2
vs 35.3 mos
4yr OS 74%
vs 65% vs
70%
Sonneveld,
2012
833 VAD vs PAD 41 mos CR/nCR: 15 vs 11
≥ VGPR: 14 vs 42
≥ PR: 54 vs 78
CR/nCR: 15 vs 31
≥ VGPR: 36 vs 62
≥ PR: 75 vs 88
28 vs 35 mos 5 yr OS, 55%
vs 65%
Abbreviations: TD: Thalidomide and Dexamethasone,Dex: Dexamethasone VAD: Vincristine, Adriamycin and Dexame‐
thasone, TAD: Thalidomide, Adriamycin and Dexamethasone, VD: Bortezomib and Dexamethasone, VTD: Bortezomib,
Thalidomide and Dexamethasone, RD: Lenalidomide and high-dose dexamethasone, Rd: Lenalidomide and low-dose
dexamethasone, PAD: Bortezomib, Adriamycin and Dexamethasone, vtD: reduced dose bortezomib, thalidomide and
Dexamethasone
Table 3. Published phase III studies using novel agents as part of induction therapy prior to ASCT
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6. Early versus late transplant
Only one randomized trial has compared upfront ASCT to late ASCT at the time of relapse.
Upfront ASCT improved event-free survival and quality of life compared to patients treated
with conventional chemotherapy and who underwent ASCT as rescue treatment at the time
of relapse; interestingly there was no appreciable difference in 5-year overall survival be‐
tween the arms . However, in the era of novel agents and resultant improvements in com‐
plete remission rates, the question as to whether ASCT could potentially be delayed until
disease relapse or progression has, again, resurfaced. The International Myeloma Working
Group recommends that all eligible patients be offered ASCT at some point in their disease
course and while there are no published randomized phase III trials incorporating the use of
novel agents in induction therapy to support the use of ASCT upon disease relapse, many
clinicians opt to collect stem cells early and preserve them for use following disease relapse.
We believe that upfront ASCT should be the standard of care until ongoing trials establish
that delayed ASCT after novel agents has a role.
7. Single ASCT versus tandem transplant
Tandem ASCT, as part of a more intensified treatment strategy (“total therapy”) was initial‐
ly shown to improve CR rates, EFS and OS in comparison to standard therapy. The superi‐
ority of double ASCT was later appreciated in a landmark randomized clinical trial which
demonstrated significantly improved OS, particularly in patients who had not achieved
VGPR following transplant. Several other randomized trials have also attempted to compare
single versus double ASCT and have reported conflicting results regarding the superiority
of one approach over the other. A recent meta-analysis attempted to answer this question
and concluded that tandem transplant offered no benefit in terms of disease outcomes and
was, in fact, associated with greater morbidity; however, this analysis has received criticism
due to the heterogeneity of the selected studies which were evaluated as well as variability
in treatment methodology. A more recent analysis suggests that tandem ASCT does offer a
survival benefit. Most clinicians speculate that tandem and single transplants are equivocal,
however, there have been no definitive trials evaluating this issue and it remains an area of
considerable debate.
8. Methods to improve conditioning regimens: The addition of total body
irradiation or other agents to high-dose melphalan
The quality of disease response following pre-transplant conditioning is critical to the suc‐
cess of ASCT. High dose melphalan 200mg/m2 is the standard conditioning chemotherapy
regimen prior to autologous HSCT in multiple myeloma as this approach has demonstrated
superior overall survival rates in comparison to chemotherapy alone. Various approaches to
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improve responses to this conditioning regimen while minimizing toxicities have been eval‐
uated in a number of studies.
Total body irradiation (TBI) in combination with melphalan demonstrated improved CR
rates, relapse and progression rates and five year OS rates when compared to TBI and cyclo‐
phosphamide as a myeloablative conditioning regimen in myeloma patients undergoing al‐
logeneic HSCT. A landmark study, however, in which melphalan and TBI was compared
with high-dose melphalan 200mg/m2 demonstrated more rapid hematologic recovery, re‐
duced transfusion requirements, shorter hospitalization and improved survival in patients
receiving high-dose melphalan alone. As such, the routine use of TBI in conjunction with
melphalan is not widely used.
The alkylating agent, busulfan, has been used in several studies in combination melpha‐
lan with promising outcomes,  particularly  in patients  with non-remission disease at  the
time of transplant.  A recent analysis of multiple myeloma patients treated with oral bu‐
sulfan and melphalan 140mg/m2  compared to standard melphalan 200mg/m2  did demon‐
strate  improved  median  PFS  (41  mos  vs  31  mos,  p=0.009),  however,  the  increased
incidence  of  veno-occlusive  disease  and  transplant  related  mortality  counteracted  the
benefits; additionally, patients who received busulfan had less access to salvage therapies
using novel agents than patients who had relapsed following treatment with melphalan
200mg/m2.
The  Intergroupe  Francophone  du  Myelome  study  group  also  evaluated  the  efficacy  of
adding bortezomib to high-dose melphalan in a recent phase II  study and were able to
demonstrate, that, in comparison to historical controls, patients treated with the bortezo‐
mib and melphalan achieved higher  CR rates  (35% vs 11%, p=.001)  with no increase in
hematologic toxicity.
9. Novel agents as post-transplant maintenance therapy
Maintenance with interferon, steroids, and chemotherapy has been tried in many centers
for  over  30  years  with  no  clear  benefit.  Maintenance  interferon  frequently  resulted  in
worsened quality  of  life;  furthermore,  future  development  of  therapy-related myelodys‐
plastic syndrome following chemotherapy led to these maintenance treatments to fall out
of favor. The availability of novel agents and their tolerable toxicity profiles has renewed
interest in post-transplant maintenance treatment. The results of this approach have, thus
far,  been  encouraging,  including  upgrades  in  disease  responses  and  improvements  in
PFS/EFS, and OS in many studies; however, none of these agents are currently approved
in the post-transplant  setting.  The recently released consensus statement from the Inter‐
national Myeloma Working Group does not advocate for or against maintenance therapy
and recommends that the decision to use maintenance therapy be made on an individu‐
alized basis. In the following paragraph we will review various agents with a brief sum‐
mary of the randomized trials data.
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9.1. Thalidomide
Thalidomide maintenance therapy following ASCT has been evaluated in six randomized
clinical  trials  all  of  which  have  reported  a  significant  improvement  in  progression  free
survival  in  patients  receiving  thalidomide  maintenance  versus  the  comparator  arm,  but
only  3  had  shown  improvement  in  OS  by  6-9  months.  Two  meta-analyses  have  con‐
firmed  improved  OS  with  thalidomide  maintenance.  However,  most  patients  (>  50%)
eventually discontinued thalidomide, between 7 months and 2 years of treatment, due to
side  effects,  particularly  development  of  peripheral  neuropathy.  Interestingly,  thalido‐
mide maintenance does not benefit patients with poor-risk cytogenetics, and, in fact, this
patient  subset  was  shown to  have  a  shorter  survival  duration.  Similar  results  from the
Total Therapy 2 study were reported although a longer follow up showed improvement
in long-term survival in high risk disease, although the main impact was most apprecia‐
ble in patients with favorable cytogenetics.
9.2. Lenalidomide
Lenalidomide has a favorable toxicity profile,  and its  efficacy extends beyond inhibition
of the growth of myeloma cells as the drug also causes alterations within the bone mar‐
row microenvironment leading to an enhancement of immune responses, thereby making
it an ideal drug for post-transplant maintenance. Two very recently published trials from
the Cancer and Leukemia Group B (CALGB) and IFM evaluated the efficacy of lenalido‐
mide following transplant and demonstrated that lenalidomide maintenance therapy was
associated with a significant improvement in PFS compared to placebo (48 vs 30.9 mos,
and 41 vs 24 mos in the CALGB and IFM studies, respectively). The benefits of lenalido‐
mide  maintenance  were  appreciated  across  all  patient  subgroups,  including  those  with
high-risk cytogenetics,  although the data is limited to a small number pf patients in the
IFM study, β2-microglobulin and response following transplant. In the IFM-2005-02 trial,
patients were given two courses of lenalidomide as consolidation treatment which led to
an upgrade in the number of disease response with rates of CR increasing from 14% to
20%  and  responses  higher  than  or  equal  to  VGPR  from  58%  to  67%.  The  side  effects
were tolerable, mostly hematologic, and responded well to dose adjustments, supportive
growth  factor  injections  and  transfusion  support.  A  meta-analysis  by  the  International
Myeloma Working Group,  which included a  total  of  1380 patients  demonstrated a  65%
reduction  in  risk  of  disease  progression  for  patients  treated  with  lenalidomide  mainte‐
nance  therapy.  There  is  a  notable  increased  risk  of  second  cancers  in  association  with
this drug as noted by both IFM and CALGB. The IFM reported the incidence of second
cancers as 3.1 per 100 patient years, compared to 1.2 per 100 patient years in the placebo
group (p = 0.002).  In the CALGB study, 8% of patients treated with lenalidomide devel‐
oped second cancers, compared to 3% in the control arm.
9.3. Bortezomib
An interesting study to evaluate the effect of minimal residual disease, by qualitative and
real-time quantitative polymerase chain reaction (RQ-PCR) after ASCT showed that a con‐
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solidation regimen comprised of bortezomib, thalidomide, and dexamethasone (VTD) in‐
creased CRs from 15% after ASCT to 49% after VTD. Most importantly, molecular
remissions increased from 3% after ASCT to 18% after VTD. No patients had relapsed at the
time of reporting (median follow-up, 42 months). These unprecedented levels of tumor cell
reduction are very encouraging and have laid the foundation for a new area of investigation
to better evaluate the depth of treatment response in myeloma.
A subsequent randomized phase 3 study specifically assessed the efficacy and safety of con‐
solidation therapy using bortezomib, thalidomide and dexamethasone (VTD) versus thali‐
domide and dexamethasone (TD). Before starting consolidation, CR/nCR rates were not
significantly different in the VTD and TD arms (63.1% 54.7%, respectively). However, after
consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly
higher for VTD-treated versus TD-treated patients. With a median follow-up of 30.4 months
from start of consolidation, 3-year PFS was significantly longer for the VTD group compared
to TD (60% vs 48%). The VTD consolidation therapy was shown to significantly improve
clinical outcomes after ASCT.
The evaluation of novel agents in the post-transplant setting has resulted in significant im‐
provements in disease responses and survival endpoints. Moreover combination regimens
in the form of consolidation and/or long term maintenance are well tolerated with further
improvements and achievement of molecular remissions. Future studies to determine the
optimal duration of maintenance therapy are urgently needed.
10. Combined ASCT/Allogeneic Hematopoeitic Stem Cell Transplant
approaches
Early trials evaluating myeloablative allogeneic stem cell transplantation in the treatment of
multiple myeloma demonstrated improvements in relapse and progression rates attributed
to graft versus myeloma effects; however, development of graft versus host disease and in‐
fectious complications resulted in high transplant-related mortality [TRM]. A critical ad‐
vantage of allogeneic transplantation was the development of reduced intensity
conditioning (RIC) regimens that were associated with decreased toxicities and profound
graft versus tumor effects as demonstrated in early trials evaluating the efficacy of RIC in
relapsed and refractory myeloma patients. However, higher rates of disease progression and
relapse, were noted and attributed to the late use of this modality underscoring the impor‐
tance of using effective regimens early before the disease becomes refractory especially since
the goals of allogeneic transplant are curative in intent.
Combined  sequential  therapy  utilizing  ASCT for  cytoreduction  followed RIC allogeneic
transplant  (i.e.  the  auto-allo  approach)  to  exploit  the  graft  versus  myeloma  effect  has
been compared to tandem ASCT in several studies; randomization in these trials was bi‐
ological;  i.e.  patients  with  an  HLA-matched  sibling  received  RIC  allogeneic  transplant
and all  others  underwent  tandem ASCT.  The  first  published study from the  IFM com‐
pared  tandem ASCT in  219  patients  to  auto-allo  in  65  patients  with  high-risk  multiple
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myeloma and reported no significant  difference in  response rates  or  event-free  survival
between groups; however, there was an observed trend toward better overall survival in
patients  treated with tandem ASCT;  these  findings remained unchanged in  a  long-term
follow-analysis  from the  same group.  Subsequent  comparisons  have  reported improved
CR rates and PFS durations and only one has shown superior OS in auto-allo treated pa‐
tients.  However a  recently published large multi-center  phase 3 study reported that  the
auto-allo  approach  was  not  superior  to  auto-auto  in  terms  of  progression-free  survival
(43 % vs 46% at 3 years) or 3-year OS (77% vs 80%). Additionally, there was no signifi‐
cant difference in the development of grade 3-5 adverse events between groups by three
years (46% vs 42%). Further modifications to allogeneic transplantation would be needed
to  offset  the  graft  versus  myeloma  effect  as  well  as  the  increase  in  transplant-related
mortality. The Eastern Cooperative Oncology Group conducted a small trial in which 32
patients  received  non-myeloablative  matched  sibling  donor  transplant  following  ASCT
and reported a  78% ORR (30% CR and 48% PR)  with  low TRM; however  over  half  of
patients developed chronic GVHD. A recent Swedish study compared auto-allo approach
to single ASCT in 357 previously untreated multiple myeloma patients and was demon‐
strated  that  the  auto-allo  approach  was  superior  in  terms  of  PFS,  OS  and  relapse  rate
with a 12% nonrelapse mortality rate. The data remain conflicting; however, a meta-anal‐
ysis reviewing outcomes on 7 published and unpublished studies concluded that the au‐
to-allo approach offers  no benefit  compared to autologous transplant  approaches and is
associated  with  higher  TRM.  The  International  Myeloma Working  Group does  not  rec‐
ommend the routine use of allogeneic transplantation,  and, in fact,  recommends consid‐
eration of RIC transplant only in the setting of a clinical trial.
11. Novel immunotherapy strategies
The post-transplant period is the ideal time point for immunotherapy as the disease bur‐
den is, theoretically, low. Immune function remains depressed following high-dose thera‐
py  for  many  months.  Ex  vivo  expansion  and  subsequent  transfer  of  autologous
stimulated  T  cells  may  enhance  host  antitumor  immunity  and  may  also  allow  for  en‐
hancement of a post-transplant vaccination strategy against tumor-directed antigens. Ear‐
ly trials  focused on the generation of  antibodies against  myeloma specific  antigens.  The
idiotype [Id] protein has, in a number of pre-clinical studies, demonstrated powerful an‐
tibody responses that, in vitro, resulted in apoptosis of myeloma cells. However, durable
clinical responses were not seen in subsequent clinical studies.  Idiotype-pulsed dendritic
cell vaccinations following ASCT have also demonstrated that cellular immune responses
can be elicited in the context of minimal residual disease following transplantation; how‐
ever,  again,  there  is  no  definitive  evidence  that  these  vaccination  strategies  alter  the
course  of  disease.  It  has  been  suggested  that  the  immune  dysfunction  in  myeloma pa‐
tients is the primary barrier to successful vaccination strategies. A low number of T-cells
with activity against myeloma have been detected in multiple myeloma patients . Several
attempts to expand T cells,  collected from the peripheral blood of affected patients,  and
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infused after  ASCT, have shown that  rapid recovery of  T-cell  numbers can be achieved
but,  unfortunately,  with  no  clear  anti-myeloma  benefits.  The  results  of  one  interesting
study in  which myeloma patients  received the  conjugated pneumococcal  vaccine before
T-cell collection and after ASCT showed profound antibody responses, suggesting that T
cells may improve immune responses to vaccination. A subsequent study in which adop‐
tive transfer of vaccine primed autologous T-cells to the htert/survivin multipeptide vac‐
cine,  a  target  in  myeloma  cells,  corroborated  these  findings  and  demonstrated  that
vaccination  was  associated  with  robust  antibody  responses  in  most  patients;  however,
again,  there was no definitive activity directed against  myeloma cells  specifically.  Clini‐
cal  trials  building  on  the  expansion  of  T  cells  and  targeting  various  myeloma  antigen
such as MAGE A3 and NYESO1 are ongoing. Of important note, several studies focusing
on expansion of  marrow infiltrating lymphocytes  (MILs)  had yielded interesting results
with regards to antimyeloma activities, but, again, the clinical benefit was quite limited.
Several antibody trials in myeloma are ongoing. A recently published phase 1 study has
provided encouraging evidence that elotuzumab in combination with lenalidomide yields
impressive responses in relapsed and refractory myeloma; whether the responses seen in the
relapsed setting can be confirmed and implemented in patients with minimal disease states
would require further investigation. In light of these findings, it is suggested that enhance‐
ment of T-cell function could potentially lay the groundwork for subsequent trials aimed to
improve immune function, and by extension, clinical outcomes following ASCT in myeloma
patients.
12. Salvage ASCT for relapsed disease
At present, the optimal treatment approach for patients with relapsed disease following ini‐
tial ASCT has not yet been defined. Potential options include treatment with novel agents,
conventional chemotherapy or a second salvage ASCT. While the data evaluating the role of
a second ASCT are limited, several small retrospective analyses have demonstrated that it is
an effective and well tolerated treatment option with overall response rates reported be‐
tween 55-90%. Overall survival and progression free survival is significantly improved for
patients who have received fewer lines of therapy prior to transplant and for those who
have experienced a late disease relapse. However, the length of time which constitutes a late
relapse has varied between studies, ranging between 12 months and > 36 months. A recently
published retrospective review suggested a time-dependent association between remission
duration following initial ASCT and PFS following transplant. Patients who relapsed within
18 months of initial ASCT had significantly shorter PFS compared to those who relapsed be‐
tween 18 and 36 months and those who relapsed 36 months or more (4.2 mos vs 13.8 mos vs
49.1 mos) [111]. Although larger studies would provide greater insight regarding the opti‐
mal timing of a second transplant, consideration of salvage ASCT is generally regarded as
feasible approach which offers the greatest benefit in select patients who have relapsed at
least more than 12 months after their initial ASCT. Salvage allogeneic transplant following
failure of initial autografting has also been compared to salvage ASCT in a limited number
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of studies and has been reported to have comparable PFS due to lower rates of disease pro‐
gression following allogeneic transplant, but superior OS in autografted patients; further‐
more, the increased incidence of graft versus host disease in allografted patients has
rendered this approach less preferable. Refinements in allogeneic transplant techniques may
potentially generate renewed interest in this treatment approach.
13. Conclusion
The widespread implementation of autologous stem cell transplantation, in conjunction
with novel agents, has revolutionized the management of multiple myeloma and has mark‐
edly altered the natural history of the disease by improving disease responses and response
duration, which, by extension, have led to significant improvements in overall survival.
While treatment options for multiple myeloma have expanded considerably over the past
several decades, long-term survivorship remains low. Continued investigative efforts are
targeted towards refining our current treatment modalities with the hope of ultimately de‐
veloping a treatment approach which results in cure.
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